Pf377 acalabrutinib with obinutuzumab in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: 3-year follow-upJ.A. Woyach,K. Rogers,S. Bhat,J. Blachly,M. Jianfar,M.M. Frigault,A. Hamdy,R. Izumi,V. Munugalavadla,C. Quah,M.H. Wang,J.C. ByrdHemaSphere(2019)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要